Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer

Griet Hoste, Laurence Slembrouck, Lynn Jongen, Kevin Punie, Tom Matton, Sara Vander Borght, Isabelle Vanden Bempt, Johan Menten, Hans Wildiers, Giuseppe Floris, Carlos Arteaga, Patrick Neven

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

We present the case of a postmenopausal patient with a secondary metastatic ER-positive, HER2-negative breast cancer who was successfully treated with fulvestrant and alpelisib following six lines of therapy. The tumour showed two uncommon PIK3CA mutations, and with the combination of alpelisib and fulvestrant the patient went from ECOG grade 3, before the start of this therapy, to ECOG grade 1 during treatment until progressive disease after 6 months. This unexpected benefit emphasizes the importance of performing a Next Generation Sequencing (NGS)-based assay to screen for several cancer genes in the metastatic setting, even after more than four lines of therapy and a high ECOG grade. Moreover, the use of alpelisib may be beneficial for uncommon PIK3CA mutations.

Original languageEnglish (US)
Pages (from-to)1071-1075
Number of pages5
JournalClinical Drug Investigation
Volume38
Issue number11
DOIs
StatePublished - Nov 1 2018

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer'. Together they form a unique fingerprint.

  • Cite this

    Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C., & Neven, P. (2018). Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. Clinical Drug Investigation, 38(11), 1071-1075. https://doi.org/10.1007/s40261-018-0696-3